ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2015
Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 122 citations in OpenAlex.
- Is there a rationale for pulmonary rehabilitation following successful chemotherapy for tuberculosis?Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e TisilogiaPooled it
- Clinical and cost effectiveness of pulmonary rehabilitation for people with post-tuberculosis lung disease in Kyrgyzstan: a single-blind randomized controlled trial.Annals of the American Thoracic Society · 2026Trial
- Randomized, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Oral Doses of Novel Antitubercular Drug Candidate, GSK2556286, in Healthy Adults.Journal of clinical pharmacology · 2026Trial
- Long non-coding RNAs in tuberculosis: Immune regulation and clinical biomarker potential.iScience · 2026Review
- Beyond Pathogens: Modulating the Commensal Microbiota to Reshape Immunity for Respiratory Disease Intervention.Pathogens (Basel, Switzerland) · 2026Review
- Optimal machine learning models and factors for global infectious diseases: An ecological analysis.Infectious medicine · 2026Article
- Application of multimodal ultrasound radiomics in the diagnosis of superficial lymph node tuberculosis.BMC medical imaging · 2026Article
- Circulating non-canonical small non-coding RNAs as novel diagnostic biomarkers for tuberculosis.Microbiology spectrum · 2026Article
- The catastrophic financial burden of extrapulmonary tuberculosis and asset index-based inequality analysis: A prospective cohort study analysing patients' impoverishment.PLOS global public health · 2026Article
- Use of a convolutional neural network for direct detection of acid-fast bacilli from clinical specimens.Microbiology spectrum · 2025Article
- Bidirectional two-sample Mendelian randomization reveals causal link between genetic blood metabolites and tuberculosis.AMB Express · 2025Article
- Special Issue "Molecular Advances and Perspectives of Lung Disease".International journal of molecular sciences · 2025Article
- Global, regional, and national burden of tuberculosis due to smoking, 1990-2021: analysis for the Global Burden of Disease study.Frontiers in immunology · 2025Article
- Analysis of factors influencing latent tuberculosis infection screening using QuantiFERON-TB Gold In-Tube in people living with HIV/AIDS.Frontiers in cellular and infection microbiology · 2025Article
- The PE/PPE family proteins ofFrontiers in immunology · 2025Review
- Ag85B-induced M1 Macrophage Polarization via the TLR4/TRAF6/NF-κB Axis Leading to Bronchial Epithelial Cell Damage and TH17/Treg Imbalance.Current molecular medicine · 2025Article
- Article
- Expanding the chemical space of ester of quinoxaline-7-carboxylate 1,4-di-RSC medicinal chemistry · 2024Article
- Transcriptome analysis of the diseased intervertebral disc tissue in patients with spinal tuberculosis.BMC medical genomics · 2024Article
- Analysis of the potential regulatory mechanisms of female and latent genital tuberculosis affecting ovarian reserve function using untargeted metabolomics.Scientific reports · 2024Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 11 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite concerted efforts over the past 2 decades at developing new diagnostics, drugs, and vaccines with expanding pipelines, tuberculosis remains a global emergency. Several novel diagnostic technologies show promise of better point-of-care rapid tests for tuberculosis including nucleic acid-based amplification tests, imaging, and breath analysis of volatile organic compounds. Advances in new and repurposed drugs for use in multidrug-resistant (MDR) or extensively drug-resistant (XDR) tuberculosis have focused on development of several new drug regimens and their evaluation in clinical trials and now influence World Health Organization guidelines. Since the failure of the MVA85A vaccine 2 years ago, there have been no new tuberculosis vaccine candidates entering clinical testing. The current status quo of the lengthy treatment duration and poor treatment outcomes associated with MDR/XDR tuberculosis and with comorbidity of tuberculosis with human immunodeficiency virus and noncommunicable diseases is unacceptable. New innovations and political and funder commitment for early rapid diagnosis, shortening duration of therapy, improving treatment outcomes, and prevention are urgently required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.